Evidence map›Paper›PMID 31586420›Full record

Trial reportRheumatology (Oxford, England)2020

Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5.

Désirée van der Heijde, Philip J Mease, Robert B M Landewé, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Xuan Zhu, Gregory Ligozio and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02404350 (A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab), which is not on this map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02404350 phase3completednot on this map

A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)

TypeinterventionalSponsorNovartis PharmaceuticalsRan2015 to 2019Enrolled997ConditionsPsoriatic ArthritisArmsSecukinumab
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Psoriatic Arthritis: From Diagnosis to Treatment.Journal of clinical medicine · 2025
    Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Infections in psoriatic arthritis: association with treatment.Therapeutic advances in musculoskeletal disease · 2024
    Review
  17. Targeted Therapies in Psoriatic Arthritis-An Update.International journal of molecular sciences · 2023
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Désirée van der HeijdeDepartment of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands.
Philip J MeaseSwedish Medical Center/Providence St Joseph Health and University of Washington, Seattle, WA, USA.
Robert B M LandewéDepartment of Rheumatology, University of Amsterdam and Atrium Medical Center, Amsterdam, The Netherlands.
Proton RahmanFaculty of Medicine, Memorial University, St Johns, Newfoundland and Labrador, Canada.
Hasan TahirRheumatology, Whipps Cross Hospital, London, UK.
Atul SinghalSouthwest Rheumatology, Dallas, TX, USA.
Elke BoettcherRheumazentrum Favoriten, Vienna, Austria.
Sandra NavarraSt Luke's Medical Center, University of Santo Tomas Hospital, Manila, Philippines.
Xuan ZhuNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Gregory LigozioNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Aimee ReadieNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Shephard MpofuNovartis Pharma AG, Basel, Switzerland.
Luminita PricopNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effect of secukinumab on radiographic progression through 52 weeks in patients with PsA from the FUTURE 5 study.

methodsPatients with active PsA, stratified by prior anti-TNF use (naïve or inadequate response), were randomized to s.c. secukinumab 300 mg load (300 mg), 150 mg load (150 mg), 150 mg no load regimens or placebo at baseline, at weeks 1, 2 and 3 and every 4 weeks starting at week 4. Radiographic progression was assessed by change in van der Heijde-modified total Sharp score (vdH-mTSS; mean of two readers). Statistical analysis used a linear mixed-effects model (random slope) at weeks 24 and 52, and observed data at week 52. Assessments at week 52 included additional efficacy endpoints (non-responders imputation and mixed-effects models for repeated measures) and safety.

resultsThe majority (86.6%) of patients completed 52 weeks of treatment. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS ⩽0.5) was 91.8, 85.2 and 87.2% in 300, 150 and 150 mg no load groups, respectively, at week 52. The change in vdH-mTSS from baseline to week 52 using random slope [mean change (s.e.)] was -0.18 (0.17), 0.11 (0.18) and -0.20 (0.18) in 300, 150 and 150 mg no load groups, respectively; the corresponding observed data [mean change (s.d.)] was -0.09 (1.02), 0.13 (1.39) and 0.21 (1.15). Clinical efficacy endpoints were sustained, and no new or unexpected safety signals were reported through 52 weeks.

conclusionSecukinumab 300 and 150 mg with or without s.c. loading regimen provided sustained low rates of radiographic progression through 52 weeks of treatment.

trial registrationClinicalTrials.gov, http://clinicaltrials.gov, NCT02404350.

Indexed as

Antibodies, Monoclonal, HumanizedAntirheumatic AgentsArthritis, PsoriaticDisease ProgressionDouble-Blind MethodFemaleHumansMaleRadiographyTreatment OutcomeAntibodies, Monoclonal, HumanizedAntirheumatic Agentssecukinumabbiological therapiescytokines and inflammatory mediatorsimmunotherapyinflammationpain assessment and managementspondylarthropathies (including psoriatic arthritis)

Identifiers

PMID31586420
PMCPMC7244782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.